Moreover, although the IL1β inhibitor MLX01 only slightly reduces breast cancer metastasis to the bone, it significantly delays the onset of bone metastasis and reduces tumour growth at the primary site (Figure 3E, Figure 4E and Figure S6E). Here, IL1B is linked to neoplasm.